(Q30626592)

25 June 2017

1 reference

title

Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation (English)

1 reference

25 June 2017

1 reference

Gilbert P

1

1 reference

25 June 2017

Self S

2

1 reference

25 June 2017

Rao M

3

1 reference

25 June 2017

Naficy A

4

1 reference

25 June 2017

Clemens J

5

1 reference

25 June 2017

publication date

1 January 2001

1 reference

Journal of Clinical Epidemiology

25 June 2017

published in

1 reference

25 June 2017

volume

54

1 reference

25 June 2017

issue

1

1 reference

25 June 2017

page(s)

68-85

1 reference

Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Polyvalent Pneumococcal-Polysaccharide Immunization of Patients with Sickle-Cell Anemia and Patients with Splenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Prevention of pneumococcal infection in children with homozygous sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Clinical trial of a subunit influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Protection against Japanese encephalitis by inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

A new classification for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Estimating evolutionary distances between DNA sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

HIV type 1 coreceptors, neutralization serotypes, and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Assessment of the Protective Efficacy of Vaccines against Common Diseases Using Case-Control and Cohort Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Interpretation and estimation of vaccine efficacy under heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Seroepidemiologic Studies during a Simultaneous Epidemic of Infection with El Tor Ogawa and Classical Inaba Vibrio cholerae

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Applying Cox regression to competing risks.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Applicability of sample size calculations based on a comparison of proportions for use with the logrank test

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Pneumococcal polysaccharide vaccines: Indications, efficacy and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Six newly recognized types of Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Pneumococcal vaccine efficacy in selected populations in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Infection Caused by Streptococcus pneumoniae in Children with Sickle Cell Disease: Epidemiology, Immunologic Mechanisms, Prophylaxis, and Vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900258-4

7 January 2021

10.1016/S0895-4356(00)00258-4

Identifiers

DOI

1 reference

25 June 2017

1 reference